Current Report Filing (8-k)
January 22 2018 - 6:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
DATE
OF REPORT: January 22, 2018
DATE
OF EARLIEST REPORTED EVENT: January 18, 2018
CORIX
BIOSCIENCE, INC
.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
Wyoming
|
|
333-150548
|
|
75-3265854
|
(STATE
OR OTHER JURISDICTION OF
INCORPORATION
OR ORGANIZATION)
|
|
(COMMISSION
FILE NO.)
|
|
(IRS
EMPLOYEE IDENTIFICATION NO.)
|
16772
West Bell Road, Suite 110-471 in Surprise, Arizona 85374
|
|
18662
MacAurther Boulevard, Suite 200 in Irvine, California 92612
|
|
34225
N. 27
th
Drive, Building 5, Suite 238 in Phoenix, Arizona 85085
|
(ADDRESS
OF PRINCIPAL EXECUTIVE OFFICES)
|
|
(ADDRESS
OF FORMER PRINCIPAL EXECUTIVE OFFICES)
|
|
(ADDRESS
OF FORMER PRINCIPAL EXECUTIVE OFFICES)
|
(623)
551-5808
(ISSUER
TELEPHONE NUMBER)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter. ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
SECTION
8 – OTHER EVENTS
Item
8.01 Other Events
On
January 10, 2018, Corix Bioscience, Inc., (the “Company”) issued a press release titled “Corix Bioscience, Inc.
Announces Joint Venture with ChampRX.” The purpose of the press release was to announce a joint venture with ChampRX. The
press release is attached hereto as an Exhibit.
SECTION
9 – FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits
Exhibit
No.
|
Document
|
|
|
99.1
|
Press Release dated
January 18, 2018
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
Corix Bioscience, Inc.
|
|
|
By:
|
/s/
Michael Ogburn
|
Name:
|
Michael Ogburn
|
Title:
|
Chief Executive Officer and President
|
|
|
Dated:
|
January
22, 2018
|
Corix Bioscience (CE) (USOTC:CXBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corix Bioscience (CE) (USOTC:CXBS)
Historical Stock Chart
From Apr 2023 to Apr 2024